Physician

Internal Medicine

Dr. Antonis Antoniou practices Internal Medicine. He researched medicine at Aristotle University of Thessaloniki School of Medicine. He received awards:"Meaningful Use Stage 1 Certification". Antonis Antoniou is also published. He has 92 publications published. The lastest publication: "Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.'

Publications

---

• Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
• Cell Type Specific Enrichment Of Risk Associated Regulatory Elements At Ovarian Cancer Susceptibility Loci.
• Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
• Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk.
• Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study.
• Fallopian tube cancer presenting as inflammatory breast carcinoma: report of a case and review of the literature.
• The role of Doppler Perfusion Index as screening test in the characterization of focal liver lesions.
• Comparative results of staged and simultaneous bilateral carotid endarterectomy: a clinical study and surgical treatment.
• Information sources and level of knowledge of contraception issues among Greek women and men in the reproductive age: a country-wide survey.
• BsmI vitamin D receptor''s polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy.
• Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients.
• Breast cancer in association with thyroid disorders.
• Anthracycline-based chemotherapy of primary non-Hodgkin''s lymphoma of the testis: the hellenic cooperative oncology group experience.
• Cancer risk models: translating family history into clinical management.
• Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators o...
• Association between KRAS rs61764370 and triple-negative breast cancer--a false positive?
• Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
• The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
• Models of genetic susceptibility to breast cancer.
• Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.
• An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers.
• The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
• A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.
• The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
• Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK gen...
• Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
• Genetic models for the familial aggregation of mammographic breast density.
• Polygenic susceptibility to breast cancer and implications for prevention.
• Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.
• An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in eastern Finland: three candidate regions found.
• BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
• Polygenic inherited predisposition to breast cancer.
• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 st...
• Re: On the use of familial aggregation in population-based case probands for calculating penetrance.
• Variants in DNA double-strand break repair genes and breast cancer susceptibility.
• Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.
• After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer.
• The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
• Risk models for familial ovarian and breast cancer.
• The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.
• The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and ...
• Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
• Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
• Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.
• Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.
• Germline mutations in RAD51D confer susceptibility to ovarian cancer.
• Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1 Interacting Genes.
• A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact.
• Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
• Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
• Exploring the link between MORF4L1 and risk of breast cancer.
• Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.
• The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
• Incorporating tumour pathology information into breast cancer risk prediction algorithms.
• Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
• Common genetic variants and cancer risk in Mendelian cancer syndromes.
• Familial relative risks for breast cancer by pathological subtype: a population-based cohort study.
• Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carri...
• Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.
• Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
• Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers.
• Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.
• Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
• A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.
• Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.
• No evidence that GATA3 rs570613 SNP modifies breast cancer risk.
• Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.
• Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies.
• Polygenes, risk prediction, and targeted prevention of breast cancer.
• No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
• No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.
• The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
• Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
• RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.
• Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Gr...
• AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.
• An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 an...
• Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study.
• Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
• BRCA1 and BRCA2 cancer risks.
• Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEP...
• Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).
• Risk prediction models for familial breast cancer.
• Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
• The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
• BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
• Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
• Two ATM variants and breast cancer risk.
• A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes.
• The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
• Polygenic inheritance of breast cancer: Implications for design of association studies.

Schools

---

• Aristotle University Of Thessaloniki Faculty Of Medicine

• Va Ucsf

• VmcVa Ucsf

Doctors Specialties

---

• Internal Medicine

Accepted Insurances

---

Awards

---

• Meaningful Use Stage 1 Certification

Education

---

• Aristotle University of Thessaloniki School of Medicine

Hospital

---

• Saint Agnes Medical Center

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Pawan K. Sood, MD This Doctor is OpenDoctor Recommended.
	Dr. Wagih W. Ibrahim, MD This Doctor is OpenDoctor Recommended.
	Dr. Joohee Lee, MD This Doctor is OpenDoctor Recommended.
	Dr. Greg N. Matsubara, MD This Doctor is OpenDoctor Recommended.
	Dr. Kantam L. Gade, MD This Doctor is OpenDoctor Recommended.
	Dr. Joga S. Gahir, MD This Doctor is OpenDoctor Recommended.
	Dr. Tony C. Fernandez, MD
	Dr. Mona A. Zia, MD
	Dr. Andres R. Leon-Sanchez, MD
	Dr. Pavel Volkov, MD This Doctor is OpenDoctor Recommended.
	Dr. Gurcharan S. Sidhu, MD This Doctor is OpenDoctor Recommended.
	Ana Freixas-Hobbs, PA-C
	Dr. Daniel V. Cordoba, MD This Doctor is OpenDoctor Recommended.
	Dr. Sindhura Reddy, DO This Doctor is OpenDoctor Recommended.
	Dr. Bharat Rattan, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog